Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Doggrell
Sheila A
SA
Doggrell Biomedical Communications, School of Biomedical Sciences, University of Queensland, QLD 4072, Australia. s_doggrell@yahoo.com
D000437:Alcoholism / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D000077285:Rimonabant
D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant; C492668:surinabant